TITLE

Diagnosis of the mucopolysaccharidoses

AUTHOR(S)
Lehman, Thomas J. A.; Miller, Nicole; Norquist, Becky; Underhill, Lisa; Keutzer, Joan
PUB. DATE
December 2011
SOURCE
Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The mucopolysaccharidoses (MPSs) often present a diagnostic challenge, particularly for patients who have more slowly progressive disease phenotypes, as early disease manifestations can be subtle or non-specific. However, certain types of bone and joint involvement should always prompt consideration of an MPS diagnosis, such as early joint involvement without classic inflammatory features or erosive bone lesions, claw hand, spinal deformities or dysostosis multiplex. All such patients should be referred to a geneticist or metabolic specialist for diagnostic evaluation. The earlier the diagnosis is made, the better the potential outcome of treatment. Each type of MPS is associated both with deficient activity of a specific lysosomal enzyme that degrades specific glycosaminoglycans (GAGs) and with abnormalities in urinary GAG excretion. MPS patients usually excrete excess GAG in urine and/or have different relative proportions of types of GAG in urine as compared with age-matched normal subjects. Although urinary GAG analyses (both quantitative and qualitative) can suggest the most likely type of MPS, diagnosis must be confirmed by enzyme assay. Multiple assays may be necessary to identify the disease subtype. Correct identification of the MPS type is essential to guide treatment and management decisions.
ACCESSION #
70140368

 

Related Articles

  • Attenuated mucopolysaccharidosis: are you missing this debilitating condition? Lampe, Christina // Rheumatology;Mar2012, Vol. 51 Issue 3, p401 

    The author offers clinical information on mucopolysaccharidosis (MPS), a rare condition often misdiagnosed because of the perception that this condition is a childhood disease. He explains that patients with attenuated or slow-progressing MPS will often fail to initially receive a correct...

  • Putting collagen back in the collagen vascular disorders. Sundel, Robert P. // Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv60 

    An introduction is presented in which the editor discusses various reports within the issue on topics including mucopolysaccharidoses (MPSs), glycosaminoglycans and primary care.

  • Improved diagnostic procedures in attenuated mucopolysaccharidosis. Hendriksz, Chris // British Journal of Hospital Medicine (17508460);Feb2011, Vol. 72 Issue 2, p91 

    The article highlights the need for improved procedures to promptly diagnose attenuated mucopolysaccharidosis in older patients, and emphasizes the use of diagnostic algorithm, a step-by-step guide to its diagnosis. Details pertaining to the presenting symptoms, common misdiagnosis, genetic...

  • Observatory: New Assays.  // MLO: Medical Laboratory Observer;May2012, Vol. 44 Issue 5, p6 

    The article informs that Zacharon Pharmaceuticals and University of California,San Diego School of Medicine researchers have developed a test to detect biomarkers for mucopolysaccharidoses(MPS).

  • Overview of the mucopolysaccharidoses. Muenzer, Joseph // Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv4 

    The mucopolysaccharidoses (MPSs) are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. The MPSs are heterogeneous, progressive disorders. Patients typically appear normal at birth, but...

  • Development and validation of a ζ-globin-specific ELISA for carrier screening of the (––SEA) α thalassaemia deletion. L Tang // Journal of Clinical Pathology;Feb2009, Vol. 62 Issue 2, p147 

    AIMS: The Southeast Asian (SEA) deletion (––SEA) represents the most common determinant causing α thalassaemia in Southeast Asian countries. The embryonic ζ-globin chain has been defined as a marker for the detection of this deletion in adults. The aim of this study was to...

  • Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Killick, Emma; Morgan, Richard; Launchbury, Francesca; Bancroft, Elizabeth; Page, Elizabeth; Castro, Elena; Kote-Jarai, Zsofia; Aprikian, Armen; Blanco, Ignacio; Clowes, Virginia; Domchek, Susan; Douglas, Fiona; Eccles, Diana; Gareth Evans, D.; Harris, Marion; Kirk, Judy; Lam, Jimmy; Lindeman, Geoffrey; Mitchell, Gillian; Pachter, Nicholas // Scientific Reports;6/28/2013, p1 

    Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of...

  • Ocular manifestations as key features for diagnosing mucopolysaccharidoses. Summers, C. Gail; Ashworth, Jane L. // Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv34 

    Diagnosis of mucopolysaccharidosis (MPS) requires awareness of the multisystem disease manifestations and their diverse presentation in terms of time of onset and severity. Many patients with MPS remain undiagnosed for years and progressively develop irreversible pathologies, which ultimately...

  • Bone Mineral Density in Egyptian Children with Mucopolysaccharidoses. Koura, H. M.; EL-Katoury, A.; Abdallah, N. I.; EL-Bassyouni, H. T.; Ayoub, D. F.; Bassiouni, R. I. // Research Journal of Medicine & Medical Sciences;2009, Vol. 4 Issue 1, p100 

    The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of enzymes catalyzing the degradation of glycosaminoglycans (GAGS). The MPS are rare diseases. MPS patients present with impaired growth, reduced walking capacity and lack of adequate nutrition, which...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics